The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

[1]  H. W. Lee,et al.  Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Radich,et al.  Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy , 2013, Haematologica.

[3]  Martin C. Müller,et al.  The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. , 2013, Blood.

[4]  A. Nagler,et al.  Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC , 2012, Hematological oncology.

[5]  E. Wiemer,et al.  A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients , 2012, Clinical Cancer Research.

[6]  D. Marin,et al.  Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia , 2012, American journal of hematology.

[7]  M. Jarošová,et al.  Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting , 2012, Annals of Hematology.

[8]  D. Colomer,et al.  Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. , 2011, Leukemia research.

[9]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[10]  N. Takahashi,et al.  Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic‐Phase Chronic Myeloid Leukemia , 2010, Clinical pharmacology and therapeutics.

[11]  T. Naoe,et al.  Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic‐phase chronic myeloid leukemia: A report from the BINGO study , 2010, Cancer science.

[12]  D. Marin,et al.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Excoffier,et al.  Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows , 2010, Molecular ecology resources.

[14]  M. Pirmohamed,et al.  Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.

[15]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[16]  Simona Soverini,et al.  Response definitions and European Leukemianet Management recommendations. , 2009, Best practice & research. Clinical haematology.

[17]  R. Savic,et al.  Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.

[18]  K. Siminovitch,et al.  Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia , 2009, Clinical Cancer Research.

[19]  B. Geoerger,et al.  Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults , 2008, Clinical Cancer Research.

[20]  M. Baccarani,et al.  Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Nicholas Moore,et al.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.

[22]  H. Koepsell,et al.  Regulation of the human organic cation transporter hOCT1 , 2004, Journal of cellular physiology.

[23]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[24]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[25]  A. Schinkel,et al.  Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.

[26]  Stuart L. Beal,et al.  Commentary on Significance Levels for Covariate Effects in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  H. Koepsell,et al.  Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.

[28]  H. Koepsell,et al.  Drug excretion mediated by a new prototype of polyspecific transporter , 1994, Nature.

[29]  T. Buclin,et al.  Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. , 2011, The Lancet. Oncology.

[30]  A. Zannettino,et al.  Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity , 2010, Leukemia.

[31]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.